

Joseph Gligorov

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7133564/joseph-gligorov-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

4,960
citations

35
h-index

66
g-index

266
ext. papers

6,353
ext. citations

4
avg, IF

5.23
L-index

#	Paper	IF	Citations
180	Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. <i>Cancer</i> , 2007 , 110, 1376-84	6.4	293
179	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649	10.3	282
178	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) <i>Annals of Oncology</i> , 2014 , 25, 1871-1888	10.3	279
177	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012 , 21, 242-52	3.6	258
176	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014 , 23, 489-502	3.6	231
175	First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3lg) enhances immune responses and antitumor activity. <i>Journal of Translational Medicine</i> , 2010 , 8, 71	8.5	164
174	Preclinical pharmacology of the taxanes: implications of the differences. <i>Oncologist</i> , 2004 , 9 Suppl 2, 3-8	5.7	164
173	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. <i>Lancet Oncology</i> , 2013 , 14, 962-70	21.7	143
172	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. <i>Lancet Oncology</i> , 2012 , 13, 375-84	21.7	134
171	Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2678-84	2.2	105
170	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1016-25	21.7	103
169	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1351-60	21.7	102
168	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014 , 25, 1979-1987	10.3	101
167	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 994-1004	10.3	87
166	Adjuvant treatments for triple-negative breast cancers. <i>Annals of Oncology</i> , 2012 , 23 Suppl 6, vi40-5	10.3	79
165	Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. <i>Annals of Oncology</i> , 2008 , 19, 1110-6	10.3	79
164	1773P Mainstreamed genetic testing for French breast and ovarian cancer patients and its utility during the COVID-19 pandemic. <i>Annals of Oncology</i> , 2020 , 31, S1028	10.3	78

163	Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. <i>Clinical Chemistry</i> , 2005 , 51, 1093-101	5.5	78
162	Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. <i>Annals of Oncology</i> , 2014 , 25, 1570-7	10.3	75
161	Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 64, 198-207	7	75
160	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 1475-1495	10.3	59
159	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 437-46	4.4	56
158	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. <i>Lancet, The</i> , 2019 , 393, 2591-2598	4.0	52
157	LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) + atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). <i>Annals of Oncology</i> , 2020 , 31, S1147-S1148	10.3	50
156	Pregnancy-associated breast cancers: do they differ from other breast cancers in young women?. <i>Breast</i> , 2012 , 21, 550-5	3.6	49
155	Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged . <i>Cancer</i> , 2009 , 115, 5155-65	6.4	44
154	Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1418-24	10.3	44
153	Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. <i>European Journal of Cancer</i> , 2016 , 66, 104-13	7.5	43
152	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017 , 28, 103-109	10.3	40
151	Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 112 Suppl 1, 53-66	4.4	40
150	Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. <i>Oncologist</i> , 2012 , 17, 469-75	5.7	39
149	Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. <i>Surgical Oncology</i> , 2010 , 19, e115-23	2.5	38
148	Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. <i>Annals of Oncology</i> , 2021 , 32, 1051-1053	10.3	38
147	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 745-53	4.4	37
146	Radiotherapy for invasive breast cancer: guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 91-102	7	36

145	The extracellular domain of Her2 in serum as a biomarker of breast cancer. <i>Laboratory Investigation</i> , 2018 , 98, 696-707	5.9	35
144	Lung cancer and renal insufficiency: prevalence and anticancer drug issues. <i>Lung</i> , 2009 , 187, 69-74	2.9	34
143	Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 124-33	7	34
142	The role of taxanes in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1073-94	4.4	34
141	Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. <i>European Journal of Cancer</i> , 2017 , 86, 82-90	7.5	33
140	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. <i>Oncologist</i> , 2015 , 20, 873-9	5.7	33
139	The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 95-113	3	32
138	Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. <i>European Journal of Cancer</i> , 2017 , 82, 230-236	7.5	32
137	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40	3.3	31
136	Pertuzumab and trastuzumab: the rationale way to synergy. <i>Anais Da Academia Brasileira De Ciencias</i> , 2016 , 88 Suppl 1, 565-77	1.4	31
135	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
134	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 34-41	13.4	30
133	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. <i>British Journal of Cancer</i> , 2010 , 103, 560-6	8.7	28
132	Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 12-21	7	28
131	Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. <i>Annals of Oncology</i> , 2016 , 27, 2046-2052	10.3	26
130	Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 64, 115-28	7	25
129	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012 , 21, 20-6	3.6	24
128	Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 532-9	4	24

127	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1007-1007	2.2	24
126	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. <i>European Journal of Human Genetics</i> , 2018 , 26, 1732-1742	5.3	23
125	Cardiovascular safety profiles of aromatase inhibitors : a comparative review. <i>Drug Safety</i> , 2006 , 29, 785-801	3.0	23
124	A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. <i>European Journal of Cancer</i> , 2020 , 135, 130-146	7.5	22
123	Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. <i>Annals of Oncology</i> , 2011 , 22, 1582-1587	10.3	21
122	High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers. <i>Annals of Oncology</i> , 2021 , 32, 1294-1295	10.3	21
121	Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. <i>Cancer Medicine</i> , 2017 , 6, 2732-2744	4.8	19
120	A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. <i>Annals of Oncology</i> , 2014 , 25, 1775-1782	10.3	19
119	Drug management of prostate cancer: prevalence and consequences of renal insufficiency. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E83-9	3.3	19
118	Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. <i>Oncologist</i> , 2010 , 15, 1169-78	5.7	18
117	Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 66-72	4	17
116	Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 421-8	4.4	15
115	Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?. <i>British Journal of Cancer</i> , 2013 , 109, 1147-56	8.7	15
114	Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial 2019 ,		15
113	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021 , 146, 30-47	7.5	15
112	Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 508-9	19.4	14
111	Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes. <i>Frontiers in Oncology</i> , 2018 , 8, 112	5.3	14
110	HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 123-33	7	14

109	Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. <i>Joint Bone Spine</i> , 2000 , 67, 22-9	2.9	14
108	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. <i>Breast</i> , 2017 , 34, 89-95	3.6	13
107	Percutaneous Image-Guided Electrochemotherapy of Spine Metastases: Initial Experience. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1806-1809	2.7	13
106	Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2011 , 22, 321-8	10.3	13
105	Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1555-64	4	13
104	Propensity score to evaluate prognosis in pregnancy-associated breast cancer: Analysis from a French cancer network. <i>Breast</i> , 2018 , 40, 10-15	3.6	12
103	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. <i>SpringerPlus</i> , 2016 , 5, 45		12
102	Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 601-7	4.4	12
101	Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. <i>European Journal of Cancer</i> , 2011 , 47, 2396-402	7.5	12
100	High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). <i>Clinical Cancer Research</i> , 2018 , 24, 3053-3058	12.9	11
99	Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. <i>Oncologist</i> , 2018 , 23, 1137-1143	5.7	11
98	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 383-393	4.4	10
97	Pregnancy after breast cancer: a need for global patient care, starting before adjuvant therapy. <i>Surgical Oncology</i> , 2010 , 19, e47-55	2.5	10
96	Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. <i>Breast</i> , 2007 , 16 Suppl 3, S1-9	3.6	10
95	Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017 , 32, 247-255	3.6	9
94	Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
93	Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015 , 19, 295-302	1.3	8
92	Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. <i>Journal of Medical Economics</i> , 2012 , 15, 1167-75	2.4	8

91	Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival. <i>Clinical Breast Cancer</i> , 2011 , 11, 46-51	3	8
90	Docetaxel in the treatment of breast cancer: current experience and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 613-33	3.5	8
89	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016 , 6, S1-S10		7
88	Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2015 , 48, 13-24	2.8	6
87	The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. <i>Reviews on Recent Clinical Trials</i> , 2006 , 1, 237-49	1.2	6
86	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an pro and con discussion. <i>ESMO Open</i> , 2019 , 4, e000565	6	6
85	Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 568-568	2.2	6
84	An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. <i>PLoS ONE</i> , 2020 , 15, e0227356	3.7	6
83	Breast cancer metastasis to the spleen: a case report and literature review. <i>Oxford Medical Case Reports</i> , 2017 , 2017, omx069	0.6	5
82	Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. <i>Bone Marrow Transplantation</i> , 2006 , 37, 669-75	4.4	5
81	Supporting multidisciplinary staff meetings for guideline-based breast cancer management: a study with OncoDoc2 2007 , 656-60	0.7	5
80	Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. <i>Breast</i> , 2021 , 55, 79-90	3.6	5
79	Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy. <i>Cancer Cell International</i> , 2018 , 18, 175	6.4	5
78	IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC). <i>Annals of Oncology</i> , 2017 , 28, v105	10.3	4
77	Long-term complete response in a breast cancer patient with skeletal muscle metastases diagnosed using 18F-FDG-PET. <i>Oxford Medical Case Reports</i> , 2017 , 2017, omx002	0.6	4
76	Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC). <i>Annals of Oncology</i> , 2012 , 23, ix114-ix115	10.3	4
75	Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge". <i>Radiotherapy and Oncology</i> , 2010 , 94, 119-20; author reply 120-1	5.3	4
74	Recommandations pour la pratique clinique, Nice, Saint-Paul-de-Vence: et de trois !. <i>Oncologie</i> , 2009 , 11, 495-496	1	4

73	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 197, 113968	3.5	4
72	Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?. <i>European Journal of Cancer</i> , 2020 , 136, 1-3	7.5	3
71	Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. <i>European Journal of Cancer</i> , 2017 , 81, 151-160	7.5	3
70	Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1825-36	3.5	3
69	A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. <i>New England Journal of Medicine</i> , 1999 , 341, 1475-6	59.2	3
68	Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study 2013 ,		3
67	Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) 2018 ,		3
66	Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. <i>European Journal of Medical Genetics</i> , 2020 , 63, 104098	2.6	3
65	Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial. <i>Annals of Oncology</i> , 2019 , 30, v141	10.3	2
64	Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e454-5; author reply e456-7	2.2	2
63	Cancer du sein 2007 ,		2
62	Taxane therapy for early stage breast cancer. <i>Women's Health</i> , 2006 , 2, 99-114	3	2
61	Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study) 2017 ,		2
60	Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé La Grossesse) network. <i>Breast</i> , 2020 , 54, 311-318	3.6	2
59	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
58	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
57	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102229	14.4	2
56	Patients with delirium and advanced solid cancer in the emergency department: A challenge for the emergency practitioner, oncologist, and intensivist. <i>Cancer</i> , 2017 , 123, 704-705	6.4	1

55	A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. <i>Chemotherapy</i> , 2016 , 61, 15-22	3.2	1
54	Juste dix ans. <i>Oncologie</i> , 2013 , 15, 565-566	1	1
53	Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. <i>Clinical Breast Cancer</i> , 2017 , 17, 107-116	3	1
52	Acute kidney failure with renal carcinomatous lymphangitis secondary to advanced colon cancer. <i>Kidney International</i> , 2013 , 84, 420	9.9	1
51	Cancer du sein m̄tastatique. <i>Oncologie</i> , 2008 , 10, 136-148	1	1
50	Cancers du Sein M̄tastatique. <i>Oncologie</i> , 2006 , 8, 36-50	1	1
49	Y a-t-il une possibilit̄ qu'au court ou moyen terme un d̄pistage et une pr̄vention du cancer de lâŕvaire soient efficaces?. <i>Oncologie</i> , 2005 , 7, 531-536	1	1
48	Creating Synthetic Patients to Address Interoperability Issues: A Case Study with the Management of Breast Cancer Patients. <i>Studies in Health Technology and Informatics</i> , 2020 , 275, 177-181	0.5	1
47	Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Assocī la Grossesse) network.. <i>Breast</i> , 2022 , 61, 168-174	3.6	1
46	A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS625-TPS625	2.2	1
45	Efficacy of epirubicin-paclitaxel (EPI-TAX) prior to high-dose chemotherapy (HDCT) in germ cell tumors (GCTs): A 17-year experience.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4557-4557	2.2	1
44	Optimisation du nomogramme de r̄ponse ^ la chimioth̄rapie n̄o-adjuvante du MDACC pour un sch̄ma utilisant plus de 4 cycles d'anthracycline 2012 , 358-359		1
43	Predicting the likelihood of recurrence of pregnancy-associated breast cancer: Nomogram based on analysis of the French cancer network: Cancer Assocī La Grossesse. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021 , 50, 101766	1.9	1
42	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. <i>Future Oncology</i> , 2021 , 17, 151-157	3.6	1
41	Early HER2-positive breast cancers: time for a new revolution?. <i>Lancet Oncology, The</i> , 2018 , 19, 12-13	21.7	1
40	Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	1
39	Estramustine : quelle place en 2010 dans le cancer du sein m̄tastatique ?. <i>Oncologie</i> , 2010 , 12, 341-348	1	0
38	Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Assocī La Grossesse) network. <i>Acta Oncologica</i> , 2021 , 1-7	3.2	0

- 37 Severe acute respiratory syndrome Coronavirus 2 infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible?. *International Journal of Cancer*, **2020**, 147, 3576-3578 7.5
- 36 Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. *Journal of Onco-Nephrology*, **2017**, 1, 213-219 0.2
- 35 Chimiothérapie des tumeurs trophoblastiques gestationnelles à haut risque. *Oncologie*, **2014**, 16, 291-299 1
- 34 Cáncer de mama inflamatorio. *EMC - Ginecología-Obstetricia*, **2017**, 53, 1-9 0
- 33 Looking for predictive markers in breast cancer--authors' reply. *Lancet Oncology, The*, **2015**, 16, e1-2 21.7
- 32 Une première collaboration entre Oncologie et la Fédération Française de Cancérologie Digestive (FFCD) !. *Oncologie*, **2014**, 16, 483-483 1
- 31 Le privilège d'une spécialité en mouvement. *Oncologie*, **2014**, 16, 1-2 1
- 30 Modification du métabolisme tumoral au cours du traitement : suivi de la réponse thérapeutique par tomographie par émission de positons. *Oncologie*, **2013**, 15, 448-453 1
- 29 Candidoses oropharyngées (COP) et cancers solides. *Oncologie*, **2011**, 13, 167-174 1
- 28 4e Recommandations pour la pratique clinique de Nice-St-Paul-de-Vence. *Oncologie*, **2011**, 13, 605-607 1
- 27 Femmes à haut risque de cancer mammaire : vers des unités et réseaux de surveillance. *Imagerie De La Femme*, **2011**, 21, 3-11 0.1
- 26 Recherche clinique: gagner la partie d'âhéc. *Oncologie*, **2009**, 11, 315-316 1
- 25 La recherche clinique dans le domaine du cancer du sein: état des lieux et perspectives. *Oncologie*, **2009**, 11, 319-324 1
- 24 L'avenir de l'oncologie médicale française est en danger. *Oncologie*, **2009**, 11, 311-311 1
- 23 Pourquoi il est urgent de renforcer l'oncologie médicale. *Oncologie*, **2010**, 12, 115-116 1
- 22 Détermination de HER2 dans les adhocarcinomes pour établir le pronostic et prédire la réponse aux traitements. *Oncologie*, **2010**, 12, 416-421 1
- 21 Connaissances et progrès. *Oncologie*, **2010**, 12, 301-302 1
- 20 Pronostic et prédiction de la réponse aux traitements par la biologie des cancers: une opportunité pour changer les concepts par l'innovation. *Oncologie*, **2010**, 12, 383-383 1

19	Determination de HER2 dans les adhocarcinomes pour établir le pronostic et prédire la réponse aux traitements. <i>Bio Tribune Magazine</i> , 2010 , 36, 30-35	
18	Hormonothérapie concomitante: application au traitement adjuvant des cancers du sein. <i>Oncologie</i> , 2007 , 9, 466-469	1
17	Spécificité de la chimiothérapie chez le sujet âgé. <i>Oncologie</i> , 2007 , 9, 783-789	1
16	Intensité de dose dans le traitement du cancer du sein. <i>Oncologie</i> , 2007 , 9, 814-820	1
15	From politics to economics: new deal in cancer war. <i>Oncologie</i> , 2008 , 10, 301-302	1
14	Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies. <i>Targeted Oncology</i> , 2006 , 1, 228-238	5
13	Quoi de neuf docteur?. <i>Oncologie</i> , 2006 , 8, 621-622	1
12	Résistances à l'hormonothérapie dans le cancer du sein. <i>Oncologie</i> , 2006 , 8, 762-766	1
11	Modalités d'utilisation et apport du trastuzumab en situation adjuvante. <i>Oncologie</i> , 2006 , 8, 748-753	1
10	Actualité de l'ASCO 2004 par localisations. <i>Oncologie</i> , 2004 , 6, 321-323	1
9	Du progrès: à croire, de le démontrer et à avoir accès. Propos des nouvelles thérapies en cancérologie. L'exemple du trastuzumab. <i>Oncologie</i> , 2005 , 7, s100-s102	1
8	Essais cliniques français en cancérologie. Résultats du premier recensement. <i>Oncologie</i> , 2005 , 7, s103-s103	1
7	Genetic abnormalities in synovial sarcoma. <i>New England Journal of Medicine</i> , 1998 , 338, 1699	59.2
6	Thrombose réversible de l'artère pulmonaire. <i>Revue De Medecine Interne</i> , 1995 , 16, 265s-266s	0.1
5	Densité de dose et intensité de dose dans le traitement adjuvant du cancer du sein 2006 , 437-453	
4	Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 603-603	2.2
3	Incidence and Risk Factors for Central Venous Catheter-Related Venous Thromboembolism in Breast Cancer Patients Under Neoadjuvant Chemotherapy: the Caveccas (Catheter Veineux Central et Cancer du Sein) Study. <i>Blood</i> , 2016 , 128, 2607-2607	2.2
2	Critères de choix d'une chimiothérapie néoadjuvante 2013 , 92-112	

- 1 STANDARDS OF CARE AND OPTIMAL OPTIONS FOR LUMINAL ABC. *Breast*, **2019**, 48, S27-S28 3.6